Next-generation sequencing technology in prostate cancer diagnosis, prognosis, and personalized treatment

Urologic Oncology: Seminars and Original Investigations

Volumn 33, Issue 6, 2015, Pages 267.e1-267.e13

  Yadav, Shalini S ^a   Li, Jinyi ^a   Lavery, Hugh J ^a   Yadav, Kamlesh K ^a   Tewari, Ashutosh K ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

NGS; Precision Medicine; Prostate Cancer

Indexed keywords

ANDROGEN RECEPTOR; BISULFITE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P53; PROTEIN TYROSINE KINASE; RAF PROTEIN; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR ETS; TRANSCRIPTOME;

CANCER DIAGNOSIS; CANCER PROGNOSIS; CHROMATIN IMMUNOPRECIPITATION; DNA METHYLATION; DNA REPAIR; EPIGENETICS; EXOME; GENE FUSION; GENE SEQUENCE; GENETIC HETEROGENEITY; GENOME; HUMAN; IMMUNE RESPONSE; INFLAMMATION; NEUROENDOCRINE PROSTATE CANCER; NEUROENDOCRINE TUMOR; NEXT GENERATION SEQUENCING; NONHUMAN; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RNA SEQUENCE; SIGNAL TRANSDUCTION; SINGLE CELL ANALYSIS; GENETIC PREDISPOSITION; HIGH THROUGHPUT SEQUENCING; MALE; PATHOLOGY; PROGNOSIS; PROSTATIC NEOPLASMS;

GENETIC PREDISPOSITION TO DISEASE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; PRECISION MEDICINE; PROGNOSIS; PROSTATIC NEOPLASMS;

EID: 84929954015     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2015.02.009     Document Type: Review

References (75)

1. Trop I., LeBlanc S.M., David J., Lalonde L., Tran-Thanh D., Labelle M., et al. Molecular classification of infiltrating breast cancer: toward personalized therapy. Radiographics 2014, 34:1178-1195.
2. Rabbani B., Tekin M., Mahdieh N. The promise of whole-exome sequencing in medical genetics. J Hum Genet 2014, 59:5-15.
3. Fang Z., Cui X. Design and validation issues in RNA-seq experiments. Brief Bioinform 2011, bbr004.
4. Bock C., Tomazou E.M., Brinkman A.B., Müller F., Simmer F., Gu H., et al. Quantitative comparison of genome-wide DNA methylation mapping technologies. Nat Biotechnol 2010, 28:1106-1114.
5. Smith I.M., Mithani S.K., Mydlarz W.K., Chang S.S., Califano J.A. Inactivation of the tumor suppressor genes causing the hereditary syndromes predisposing to head and neck cancer via promoter hypermethylation in sporadic head and neck cancers. ORL J Otorhinolaryngol Relat Spec 2010, 72:44-50.
6. Furey T.S. ChIP-seq and beyond: new and improved methodologies to detect and characterize protein-DNA interactions. Nat Rev Genet 2012, 13:840-852.
7. Chen Y., Chi P., Rockowitz S., Iaquinta P.J., Shamu T., Shukla S., et al. ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss. Nat Med 2013, 19:1023-1029.
8. Roychowdhury S., Iyer M.K., Robinson D.R., Lonigro R.J., Wu Y.M., Cao X., et al. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med 2011, 3:111ra121.
9. Spencer D.H., Sehn J.K., Abel H.J., Watson M.A., Pfeifer J.D., Duncavage E.J. Comparison of clinical targeted next-generation sequence data from formalin-fixed and fresh-frozen tissue specimens. J Mol Diagn 2013, 15:623-633.
10. Choudhary A., Mambo E., Sanford T., Boedigheimer M., Twomey B., Califano J., et al. Evaluation of an integrated clinical workflow for targeted next-generation sequencing of low-quality tumor DNA using a 51-gene enrichment panel. BMC Med Genomics 2014, 7:62.
11. Teo S.M., Pawitan Y., Ku C.S., Chia K.S., Salim A. Statistical challenges associated with detecting copy number variations with next-generation sequencing. Bioinformatics 2012, 28:2711-2718.
12. Barbieri C.E., Bangma C.H., Bjartell A., Catto J.W.F., Culig Z., Grönberg H., et al. The mutational landscape of prostate cancer. Eur Urol 2013, 64:567-576.
13. Berger M.F., Lawrence M.S., Demichelis F., Drier Y., Cibulskis K., Sivachenko A.Y., et al. The genomic complexity of primary human prostate cancer. Nature 2011, 470:214-220.
14. Barbieri C.E., Baca S.C., Lawrence M.S., Demichelis F., Blattner M., Theurillat J.P., et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet 2012, 44:685-689.
15. Baca S.C., Prandi D., Lawrence M.S., Mosquera J.M., Romanel A., Drier Y., et al. Punctuated evolution of prostate cancer genomes. Cell 2013, 153(3):666-677.
16. Ewing C.M., Ray A.M., Lange E.M., Zuhlke K.A., Robbins C.M., Tembe W.D., et al. Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med 2012, 366:141-149.
17. Chen M., Pratt C.P., Zeeman M.E., Schultz N., Taylor B.S., O'Neill A., et al. Identification of PHLPP1 as a tumor suppressor reveals the role of feedback activation in PTEN-mutant prostate cancer progression. Cancer Cell 2011, 20:173-186.
18. Taylor B.S., Schultz N., Hieronymus H., Gopalan A., Xiao Y., Carver B.S., et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010, 18:11-22.
19. Grasso C.S., Wu Y.M., Robinson D.R., Cao X., Dhanasekaran S.M., Khan A.P., et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012, 487:239-243.
20. Beltran H., Rickman D.S., Park K., Chae S.S., Sboner A., MacDonald T.Y., et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov 2011, 1:487-495.
21. Palanisamy N., Ateeq B., Kalyana-Sundaram S., Pflueger D., Ramnarayanan K., Shankar S., et al. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med 2010, 16:793-798.
22. Tomlins S.A., Rhodes D.R., Perner S., Dhanasekaran S.M., Mehra R., Sun X.-W., et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005, 310:644-648.
23. Tomlins S.A., Aubin S.M.J., Siddiqui J., Lonigro R.J., Sefton-Miller L., Miick S., et al. Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med 2011, 3:94ra72.
24. Fine S.W., Gopalan A., Leversha M.A., Al-Ahmadie H.A., Tickoo S.K., Zhou Q., et al. TMPRSS2-ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features. Mod Pathol 2010, 23:1325-1333.
25. Gopalan A., Leversha M.A., Satagopan J.M., Zhou Q., Al-Ahmadie H.A., Fine S.W., et al. TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res 2009, 69:1400-1406.
26. Wang X. Development of peptidomimetic inhibitors of the ERG transcription factor in prostate cancer. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research. vol. 73. Washington, DC: 2013.
27. Brenner J.C., Ateeq B., Li Y., Yocum A.K., Cao Q., Asangani I.A., et al. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell 2011, 19:664-678.
28. Dang C.V. MYC, metabolism, cell growth, and tumorigenesis. Cold Spring Harb Perspect Med 2013, 3.
29. Bernard D., Pourtier-Manzanedo A., Gil J., Beach D.H. Myc confers androgen-independent prostate cancer cell growth. J Clin Invest 2003, 112:1724-1731.
30. Lindberg J., Mills I.G., Klevebring D., Liu W., Neiman M., Xu J., et al. The mitochondrial and autosomal mutation landscapes of prostate cancer. Eur Urol 2013, 63(4):702-708.
31. Jiang Y., Palma J.F., Agus D.B., Wang Y., Gross M.E. Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer. Clin Chem 2010, 56:1492-1495.
32. Ryan C.J., Smith M.R., de Bono J.S., Molina A., Logothetis C.J., de Souza P., et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013, 368:138-148.
33. Tran C., Ouk S., Clegg N.J., Chen Y., Watson P.A., Arora V., et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009, 324:787-790.
34. Cai C., Chen S., Ng P., Bubley G.J., Nelson P.S., Mostaghel E.A., et al. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res 2011, 71:6503-6513.
35. Antonarakis E.S., Lu C., Wang H., Luber B., Nakazawa M., Roeser J.C., et al. AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer. N Engl J Med 2014, 371:1028-1038.
36. Thadani-Mulero M., Portella L., Sun S., Sung M., Matov A., Vessella R.L., et al. Androgen receptor splice variants determine taxane sensitivity in prostate cancer. Cancer Res 2014, 74:2270-2282.
37. Tay Y., Kats L., Salmena L., Weiss D., Tan S.M., Ala U., et al. Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs. Cell 2011, 147:344-357.
38. Beltran H., Yelensky R., Frampton G.M., Park K., Downing S.R., MacDonald T.Y., et al. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Eur Urol 2013, 63:920-926.
39. Donovan M.J., Cordon-Cardo C. Predicting high-risk disease using tissue biomarkers. Curr Opin Urol 2013, 23:245-251.
40. Conley-LaComb M.K., Saliganan A., Kandagatla P., Chen Y.Q., Cher M.L., Chinni S.R. PTEN loss mediated Akt activation promotes prostate tumor growth and metastasis via CXCL12/CXCR4 signaling. Mol Cancer 2013, 12:85.
41. Radu A., Neubauer V., Akagi T., Hanafusa H., Georgescu M.-M. PTEN induces cell cycle arrest by decreasing the level and nuclear localization of cyclin D1. Mol Cell Biol 2003, 23:6139-6149.
42. Paramio J.M., Navarro M., Segrelles C., Gómez-Casero E., Jorcano J.L. PTEN tumour suppressor is linked to the cell cycle control through the retinoblastoma protein. Oncogene 1999, 18:7462-7468.
43. Bakin R.E., Gioeli D., Sikes R.A., Bissonette E.A., Weber M.J. Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Res 2003, 63:1981-1989.
44. Martelli A.M., Evangelisti C., Follo M.Y., Ramazzotti G., Fini M., Giardino R., et al. Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in cancer stem cells. Curr Med Chem 2011, 18:2715-2726.
45. Wang X.S., Shankar S., Dhanasekaran S.M., Ateeq B., Sasaki A.T., Jing X., et al. Characterization of KRAS rearrangements in metastatic prostate cancer. Cancer Discov 2011, 1(1):35-43.
46. Berger R., Lin D.I., Nieto M., Sicinska E., Garraway L.A., Adams H., et al. Androgen-dependent regulation of Her-2/neu in prostate cancer cells. Cancer Res 2006, 66:5723-5728.
47. Ateeq B., Tomlins S.A., Laxman B., Asangani I.A., Cao Q., Cao X., et al. Therapeutic targeting of SPINK1-positive prostate cancer. Sci Transl Med 2011, 3:72ra17.
48. Rubin M.A., Maher C.A., Chinnaiyan A.M. Common gene rearrangements in prostate cancer. J Clin Oncol 2011, 29:3659-3668.
49. Huang S., Gulzar Z.G., Salari K., Lapointe J., Brooks J.D., Pollack J.R. Recurrent deletion of CHD1 in prostate cancer with relevance to cell invasiveness. Oncogene 2012, 31:4164-4170.
50. Xu K., Wu Z.J., Groner A.C., He H.H., Cai C., Lis R.T., et al. EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science 2012, 338:1465-1469.
51. Qi W., Chan H., Teng L., Li L., Chuai S., Zhang R., et al. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc Natl Acad Sci U S A 2012, 109:21360-21365.
52. Asangani I.A., Dommeti V.L., Wang X., Malik R., Cieslik M., Yang R., et al. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature 2014, 510:278-282.
53. Mertz J.A., Conery A.R., Bryant B.M., Sandy P., Balasubramanian S., Mele D.A., et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci U S A 2011, 108:16669-16674.
54. Wee Z.N., Li Z., Lee P.L., Lee S.T., Lim Y.P., Yu Q. EZH2-mediated inactivation of IFN-γ-JAK-STAT1 signaling is an effective therapeutic target in MYC-driven prostate cancer. Cell Rep 2014, 8:204-216.
55. Zitvogel L., Kepp O., Galluzzi L., Kroemer G. Inflammasomes in carcinogenesis and anticancer immune responses. Nat Immunol 2012, 13:343-351.
56. FitzGerald L.M., Kumar A., Boyle E.A., Zhang Y., McIntosh L.M., Kolb S., et al. Germline missense variants in the BTNL2 gene are associated with prostate cancer susceptibility. Cancer Epidemiol Biomarkers Prev 2013, 22(9):1520-1528.
57. Sharma N.L., Massie C.E., Ramos-Montoya A., Zecchini V., Scott H.E., Lamb A.D., et al. The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man. Cancer Cell 2013, 23:35-47.
58. Li C., Ao J., Fu J., Lee D.F., Xu J., Lonard D., et al. Tumor-suppressor role for the SPOP ubiquitin ligase in signal-dependent proteolysis of the oncogenic co-activator SRC-3/AIB1. Oncogene 2011, 30:4350-4364.
59. Zhang D., Wang H., Sun M., Yang J., Zhang W., Han S. Speckle-type POZ protein, SPOP, is involved in the DNA damage response. Carcinogenesis 2014, 35(8):1691-1697.
60. Burkhardt L., Fuchs S., Krohn A., Masser S., Mader M., Kluth M. CHD1 Is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer. Cancer Res 2013, 73:2795-2805.
61. Abate-Shen C., Shen M.M., Gelmann E. Integrating differentiation and cancer: the Nkx3.1 homeobox gene in prostate organogenesis and carcinogenesis. Differentiation 2008, 76:717-727.
62. Asatiani E., Huang W.X., Wang A., Rodriguez Ortner E., Cavalli L.R., Haddad B.R. Deletion, methylation, and expression of the NKX3.1 suppressor gene in primary human prostate cancer. Cancer Res 2005, 65:1164-1173.
63. Robbins C.M., Tembe W.A., Baker A., Sinari S., Moses T.Y., Beckstrom-Sternberg S. Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors. Genome Res 2011, 21:47-55.
64. Menon R., Deng M., Rüenauver K., Queisser A., Peifer M., Pfeifer M. Somatic copy number alterations by whole-exome sequencing implicates YWHAZ and PTK2 in castration-resistant prostate cancer. J Pathol 2013, 231:505-516.
65. Sharma A., Yeow W.-S., Ertel A., Coleman I., Clegg N., Thangavel C. The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. J Clin Invest 2010, 120:4478-4492.
66. Otto T., Horn S., Brockmann M., Eilers U., Schüttrumpf L., Popov N. Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell 2009, 15:67-78.
67. Beltran H., Rubin M.A., Mosquera J.M., Christos P.J., Calukovic O., Karpenko I. A phase II trial of the aurora kinase A inhibitor MLN8237 in patients with metastatic castrate resistant and neuroendocrine prostate cancer. J Clin Oncol 2013, (suppl; abstr TPS5096):31.
68. Maher C.A., Wilson R.K. Chromothripsis and human disease: piecing together the shattering process. Cell 2012, 148:29-32.
69. Lin P.C., Giannopoulou E.G., Park K., Mosquera J.M., Sboner A., Tewari A.K. Epigenomic alterations in localized and advanced prostate cancer. Neoplasia 2013, 15:373-383.
70. Forshew T., Murtaza M., Parkinson C., Gale D., Tsui D.W.Y., Kaper F. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med 2012, 4:136ra68.
71. Branton D., Deamer D.W., Marziali A., Bayley H., Benner S.A., Butler T. The potential and challenges of nanopore sequencing. Nat Biotechnol 2008, 26:1146-1153.
72. Ohshiro T., Matsubara K., Tsutsui M., Furuhashi M., Taniguchi M., Kawai T. Single-molecule electrical random resequencing of DNA and RNA. Sci Rep 2012, 2:501.
73. Schloss J.A. How to get genomes at one ten-thousandth the cost. Nat Biotechnol 2008, 26:1113-1115.
74. Jung K., LePendu P., Chen W.S., Iyer S.V., Readhead B., Dudley J.T. Automated detection of off-label drug use. PloS One 2014, 9:e89324.
75. Kasap C., Elemento O., Kapoor T.M. DrugTargetSeqR: a genomics- and CRISPR-Cas9-based method to analyze drug targets. Nat Chem Biol 2014, 10:626-628.